Meloxicam pharmacokinetics in renal impairment

British Journal of Clinical Pharmacology

Volumn 43, Issue 1, 1997, Pages 35-40

  Boulton Jones, J M ^a   Geddes, C G ^a   Heinzel, G ^b   Turck D ^b   Nehmiz, G ^b   Bevis, P J R ^c  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c BOEHRINGER INGELHEIM LTD   (United Kingdom)

Author keywords

Meloxicam; Pharmacokinetics; Renal impairment; Tolerability

Indexed keywords

MELOXICAM;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG TOLERANCE; FEMALE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL;

EID: 0031028195     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1997.tb00030.x     Document Type: Article

References (30)

1. Engelhardt G. Meloxicam a potent inhibitor of COX-2. Data presented at 9th International Conference on Prostaglandins and Related Compounds, Florence, Italy 6-10 June 1994, P.82.
2. Vane JR. Towards a better aspirin. Nature 1994; 367: 215-216.
3. Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 1995; 44. 1-10.
4. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993; 268: 6610-6614.
5. Schmid J, Busch U, Heinzel G, Bozler G, Kaschke S, Kummer M, Meloxicam: pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects. Drug Metab Disp 1995; 23: 1206-12.
6. Türck D, Roth W, Busch U. A review of the clinical pharmacokinetics of meloxicam. BrJ Rheumatol 1996; 35(suppl 1): 13-16.
7. Türck D, Busch U, Heinzel E, Narjes H, Nehmiz G. Effect of food on the pharmacokinetics of meloxicam after oral administration. Clin Drug Invest 1995; 9: 270-276.
8. Lin JH, Cocchecto DM, Duggan DE. Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs. Clin Pharmacokinet 1987; 12: 402-432.
9. Anttila M, Haataja M, Kasanen A. Pharmacokinetics of naproxen in subjects with normal and impaired renal function. Eur J Clin Pharmacol 1980; 18: 263-268.
10. Narjes HH, Türck D, Schwarz A, Höffler D, Nehmiz G, Heinzel G. Pharmacokinetics of meloxicam 15 mg, single oral dose, in patients on chronic haemodialysis. Rheumatol Eur 1995; 24(suppl 3): 177.
11. Mawer EG, Knowles BR, Lucas SB, Stirland RM, Tooth JA. Computer assisted prescribing of kanamycin for patients with renal insufficiency. Lancet 1972; i: 12-15.
12. Commission of the European Communities: Good Clinical Practice for trials on medicinal products in the European Community. Rev.2, 17 August 1989.
13. Shah V, Midha K, Dighe S, et al. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Pharm Res 1992; 9: 588-92.
14. Heinzel G, Woloszczk R, Thomann P. TopFit 2.0. Pharmacokinetic and pharmacodynamic data analysis system for the PC. Gustav Fischer publ., Stuttgart-Jena-New York 1993.
15. Karch FE, Lasagna L. Adverse reactions. JAMA 1975; 234: 1236-41.
16. Commission of the European Communities: Investigation of bioavailability and bioequivalence. Guideline III/54/89.
17. Couet W, Fauvel JP, Laville M, et al. Pharmacokinetics of oral cetatrizine in patients with impaired renal function. Int J Clin Pharmacol Ther Toxicol 1991; 29: 213-7.
18. Wilkinson DR, Shand DG. A physiologic approach to hepatic clearance. Clin Pharmacol Ther 1975; 18: 377-390.
19. Müller FO, Schall R, de Vaal AC, Groenewoud G, Hundt HK, Middle MV. Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers. Eur J Clin Pharmacol 1995; 48: 247-251.
20. Busch U, Heinzel G, Narjes H, Nehmiz G. Interaction of meloxicam with cimetidine, Maalox®, or aspirin. J Clin Pharmacol 1996; 36: 79-84.
21. Gulyassy PF, Depner TA. Impaired binding of drugs and endogenous ligands in renal diseases. Am J Kid Dis 1983; 2: 578-601.
22. Stierlin H, Faigle JW, Colombi A. Pharmacokinetics of diclofenac sodium (voltaren) and metabolites in patients with impaired renal function. Scand J Rheumatol 1978; Suppl 22: 30-51.
23. Rudy AC, Figueroa NL, Hall SD, Brater DC. The pharmacokinetics of piroxicam in elderly persons with and without renal impairment. Br J Clin Pharmacol 1994; 37: 1-5.
24. Busch U, Heinzel G, Narjes H. The effect of cholestyramine on the pharmacokinetics of meloxicam, a new non-steroidal anti-inflammatory drug (NSAID), in man. Eur J Clin Pharmacol 1995; 48: 269-272.
25. Smith WL, Bell TG. Immunohistochemical localization of the prostaglandin-forming cyclooxygenase in renal cortex. Am J Physiol 1978; 235: F451-457.
26. Stokes JB. Integrated actions of renal medullary prostaglandins in the control of water excretion. Am J Physiol 1981; 240: F471-480.
27. Bonvalet JP, Pradelles P, Farman N. Segmental synthesis and actions of prostaglandins along the nephron. Am J Physiol 1987; 253: F377-387.
28. Harns RC, McKanna JA, Akal Y, Jacobson HR, Dubois RN, Breyer MD. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994; 94: 2504-2510.
29. Ryzmkiewicz D, Leingang K, Baird N, Morrison AR. Regulation of prostaglandin endoperoxidase synthase gene expression in rat mesangial cells by interleukin-1β. Am J Physiol 1994; 266: F39-45.
30. Ciabattoni G, Cinotti GA, Pierucci A, et al. Effects of sulindac and ibuprofen in patients with glomerular disease. Evidence for the dependence of renal function on prostacyclin. N Engl J Med 1984; 310: 279-283.